Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Tessa Forms $120 Million China JV to Develop Cell Therapies for Cancer

publication date: Jun 13, 2019

Tessa Therapeutics, a Singapore company, will form a $120 million JV with China-Singapore Guangzhou Knowledge City (CSGKC) to develop Tessa's oncology cell therapies in China. The companies will fund the JV in two stages, with Tessa contributing its cell therapies plus $40 million and CSGKC $80 million in cash. In the first stage, Tessa will invest $20 million plus China rights to its technology, and CSGKC will add $40 million for a 13% stake in the JV. A clinical-stage company, Tessa is developing autologous and off-the-shelf allogeneic therapies that target a range of cancers. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China